Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
1. FDA approved Obagi® saypha® MagIQ™ hyaluronic acid gel for U.S. market. 2. Launch set for 2026, expanding Obagi Medical's addressable market to $4.2 billion. 3. Obagi® saypha® MagIQ™ ensures a safe and effective aesthetic solution. 4. Collaboration with Croma-Pharma enhances product credibility and market potential. 5. Obagi Medical's growth reinforces Waldencast's strategic vision in skincare.